> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Schrödinger Nixes Leukemia Drug After 2 Deaths
- URL: https://www.fdaweb.com/schrodinger-nixes-leukemia-drug-after-2-deaths/
- Published: 2025-08-14T12:00:00.000Z
- Updated: 2026-09-14T15:19:05.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159687

Schrödinger has discontinued the clinical development program for SGR-2921, its CDC7 inhibitor being evaluated in a Phase 1 dose-escalation study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. “Despite early evidence of monotherapy activity observed in the Phase 1 study, based on the profile observed to date, including two emergent events where SGR-2921 was considered to have contributed to two deaths in patients with AML, Schrödinger believes the path to development as a combination therapy would be difficult to pursue,” a company statement says.

The Phase 1 study was based on preclinical data that demonstrated CDC7 inhibition resulted in monotherapy and combination anti-leukemic responses in patient-derived AML models, suggesting the therapy could e used in combination with standard-of-care agents, Schrödinger says.